Executive summary clinical practice guideline of postmenopausal, glucocorticoid-induced, and male osteoporosis (2022 update)*

Spanish Society for Bone and Mineral Metabolism Investigation (SEIOMM)

DOI: http://dx.doi.org/10.4321/S1889-836X2022000100002

Riancho JA1, Peris P2, González-Macías J3, Pérez-Castrillón JL4, on behalf of the SEIOMM Osteoporosis Guidelines Writing Group (listed in Annex)

1 Internal Medicine Service. Marqués de Valdecilla University Hospital and Department of Medicine and Psychiatry. University of Cantabria. IDIVAL, Santander (Spain)
2 Rheumatology Service. Hospital Clinic and University of Barcelona, IDIBAPS, CIBERehd. Barcelona (Spain)
3 Department of Medicine and Psychiatry. University of Cantabria. IDIVAL, Santander (Spain)
4 Internal Medicine Service. Río Horta University Hospital and Department of Medicine. University of Valladolid. Valladolid (Spain)

Summary
This updated version of the SEIOMM (Spanish Society for Research in Osteoporosis and Mineral Metabolism) osteoporosis guideline incorporates the most relevant information published in the last 7 years (since the 2015 guide) with imaging studies such as vertebral fracture assessment and trabecular bone score analysis. Therapeutic advances include new anabolic agents, comparative studies of drug efficacy, and sequential and combined therapy. Against this background, therapeutic algorithms were updated.

Key words: osteoporosis, fractures, densitometry, anabolic agents, anti-resorptive drugs.

1. INTRODUCTION
Seven years have passed since the most recent version of the Osteoporosis Guidelines of the Spanish Society for Bone Research and Mineral Metabolism (SEIOMM) was drawn up, using the standard methodology of evidence-based medicine1. This update incorporates information released since then. The full text is available in the Guide.

2. METHODS
A group of experts (see annex) reviewed each section to incorporate the new findings published in recent years. The new text was disseminated to other interested entities (including SEIOMM partners, patient associations, the Spanish Agency for Medicines and Health Products, and pharmaceutical industries) to provide input to the document, which was subsequently analysed by the group of experts. Osteoporosis in postmenopausal women was analysed first, followed by osteoporosis in men and glucocorticoid-induced osteoporosis.

ASSESSMENT OF PATIENTS AT RISK OF OSTEOPOROSIS
1. Clinical risk factors for fracture
The main risk factors are shown in Table 1. After suffering a first fracture, the greatest risk of suffering a new fracture occurs in the subsequent two years, especially if the first fracture was vertebral. This phenomenon led to formulating the concept of “imminent risk” of fracture.

2. Bone densitometry and imaging techniques
X-ray absorptiometry (DXA), which quantifies bone mineral density (BMD), is commonly used to estimate fracture risk. The diagnosis of osteoporosis is established with a T score <−2.5 in any of the following locations: lumbar spine, total hip, or femoral neck (Table 2). In premenopausal women and men under 50 years, the use of Z scores is recommended, with Z ≤−2.0 considered “low BMD for chronological age.” The trabecular bone score (TBS) may improve the prediction of fracture risk.

* This summary is published simultaneously in Revista Clínica Española.
https://doi.org/10.1016/j.rce.2021.12.007

Correspondence: J.A. Riancho (riancho@unican.es)
In general, DXA is recommended when risk factors are strongly associated with osteoporosis or fractures (table 1). Radiography is essential for identifying fractures. In the case of the vertebral fractures, the diagnosis requires a decrease of at least 20-25% in height. In some cases, imaging based on DXA (i.e., vertebral fracture assessment, VFA) may be an alternative.

3. Study protocol. Bone turnover markers
A complete blood count and biochemical analysis should be carried out (kidney and liver function, calcium, albumin, phosphorus, alkaline phosphatase, thyrotropin, 25-hydroxyvitamin D [25OHD], proteinogram and calciiuria). The suitability of determining parathyroid hormone (PTH) and bone turnover markers (BTM) is a subject of debate. Other studies should be performed in young patients to rule out secondary causes of osteoporosis (e.g., hypercortisolism, celiac disease, and systemic mastocytosis). DXA and evaluation of possible vertebral fractures will almost always be necessary.

Together with other risk factors, BTMs can aid in identifying patients with a higher risk of fracture and, (above all) they help early assessment of the response to treatment. The most widely used are the carboxy-terminal telopeptides of type I collagen (s-CTX, Serum C-telopeptide cross-link type I collagen) and the amino-terminal peptides of type I procollagen (procollagen type I N-terminal propeptide).

4. Risk prediction tools
A combination of clinical data and DXA is useful to assess fracture risk. Several instruments have been developed for this purpose, including FRAX, the Garvan Medical Research Institute scale, and the QFracture Index. They have a similar discriminatory capacity and are only moderately efficient. FRAX is the most widespread. Unfortunately, its adaptation to the epidemiology of fractures in Spain has been inadequate and underestimates the risk of major osteoporotic fractures.

AVAILABLE TREATMENTS FOR POSTMENOPAUSAL OSTEOPOROSIS

1. Non-pharmacological interventions
A balanced diet should be maintained, with a contribution of 1-1.5 g/kg of protein, regular physical exercise, and avoiding tobacco and excessive alcohol consumption. Fall prevention programmes and hip protectors may be helpful in some cases.

2. Calcium and vitamin D
Patients treated with drugs for osteoporosis should have an adequate intake of calcium and vitamin D4 to attain serum levels of 25OHD >25-30 ng/mL. The generally recommended dose of vitamin D is 800-1200 IU/d (or weekly or monthly equivalent). If calciediol is used, 0.266 micrograms are given every 15-30 days. Calcium intake should be 1000-1200 mg/day, preferably through diet and supplements if needed.

3. Drugs not indicated in osteoporosis
Calcitonin, strontium ranelate, PTH 1-84, isoflavones, phytoestrogens, and thibolone are not indicated for the treatment of osteoporosis. Thiazides can be used to control hypercalciuria.

4. Oestrogen therapy
Although oestrogen therapy effectively prevents fractures, its possible side effects have prevented it from being recommended as an osteoporosis treatment, except in cases of early menopause or when other alternatives are not available.

5. Selective oestrogen receptor modulators
Selective oestrogen receptor modulators (SERMs) increase spinal BMD.Raloxifene and bazedoxifene reduce vertebral fracture risk by 40% but do not influence nonvertebral fractures5. Its main complication is an increased risk of venous thromboembolic disease.

6. Bisphosphonates
6.1. Alendronate
Alendronate at 70 mg/week reduces vertebral, nonvertebral, and hip fractures by around 45%, 25–30%, and 45–55%, respectively6. Most clinical trials have included a treatment period of 3–5 years. However, a more prolonged administration may sometimes be recommended.

6.2. Risedronate
According to recent meta-analyses, risedronate reduces the risk of all fractures (vertebral 39%, hip 27% and non-vertebral 22%)7. It is administered in doses of 35 mg weekly or 75 mg two consecutive days per month. A weekly gastro-resistant formulation does not require administration on an empty stomach.

6.3. Ibendumate
This agent is less effective than other bisphosphonates (BPs) and does not appear to reduce nonvertebral fractures.

6.4. Zoledronate
Zoledronate at 5 mg/year intravenously reduces vertebral, non-vertebral and hip fractures by 70%, 25%, and 40%, respectively8. A network meta-analysis found no differences between the BPs in terms of fracture prevention, while in another two, zoledronate was more effective than other BPs.

6.5. Adverse effects of bisphosphonates
BPs are generally well tolerated. In some patients, oral BPs can cause esophagitis. They should be avoided in patients with difficulty swallowing or Barrett’s esophagus.

Acute-phase reaction or self-limited flu-like symptoms are common after the first dose of zoledronicates. BPs are not recommended in patients with a glomerular filtration rate (GFR) ≤30 mL/min. Intravenous BPs can cause hypocalcaemia, especially in patients with renal failure or insufficient intake of vitamin D or calcium.

Osteonecrosis of the jaws (ONJ) is rare but potentially severe. The risk in patients treated with BP for osteoporosis is very low (1/1,500-1/100,000 patient-years). It is related to the state of oral health (periodontitis) and dental procedures.

Atypical fractures of the femur (AFF) occur in 1-2 cases per 10,000 patients treated with BP. The risk increases with exposure time; however, this risk is very low compared to the risk of osteoporotic fractures. For each AFF that could appear, some 270 clinical fragility fractures are prevented, including 70 hip fractures8.

7. Denosumab
Denosumab reduces the risk of vertebral, non-vertebral and hip fractures by around 70%, 20%, and 40%, respectively9. It is generally well tolerated. The risks of AFF and ONJ are very low, around 1/10,000 and 1/2,000 patients/year, respectively. Denosumab can be used in pa-
tients with kidney failure, even those on dialysis. An adequate supply of calcium and vitamin D must be ensured to avoid hypocalcaemia.

After discontinuation, an increase in bone turnover markers (BMT) and a loss of BMD gained are observed. In some patients, this phenomenon is associated with multiple vertebral fractures.

8. PTH 1-34 (teriparatide)
Teriparatide exerts a bone-forming effect and reduces vertebral fracture risk by 65% and non-vertebral fractures by 50%. A meta-analysis did not show a significant reduction in hip fractures, but another three concluded that it reduced these fractures by 56–65%. It was shown to be more effective than risedronate in women with severe osteoporosis. Several biological analogues and biosimilars are marketed.

9. Abaloparitide
Abaloparitide reduces vertebral and non-vertebral fractures. It is approved in the US but not in Europe.

10. Romosozumab
Romosozumab is a sclerostin-neutralising antibody with dual anabolic and antiresorptive effects.

According to several meta-analyses, this agent reduces vertebral (66–73%), non-vertebral (33%), and hip (56%) fractures. In women with severe osteoporosis, a cycle of romosozumab provided additional benefits to alendronate.

Romosozumab is generally well tolerated; however, in some studies, a small increase in cardiovascular events was described (1.3% vs 0.9%); therefore, it is contraindicated in patients with a history of myocardial infarction or cerebrovascular accident and should be considered carefully in those with multiple cardiovascular risk factors.

11. Vertebroplasty and kyphoplasty
Although many noncontrolled studies have shown a marked analgesic effect, randomised clinical trials have provided conflicting results for vertebroplasty and kyphoplasty. Thus, they are not routinely recommended. They can be considered in patients with fractures less than 6 weeks old and severe pain despite medical treatment and in patients with fractures in 6 weeks to a year of evolution and persistent pain that responds poorly to analgesics if they show signs of oedema on MRI.

START AND FOLLOW-UP OF TREATMENT
1. Decision to commence treatment
In general, patients with some of these characteristics should be treated:

1. One or more fragility fractures, especially the vertebrae, hip, humerus, and pelvis (regardless of BMD).

2. BMD < -2.5 T score in the lumbar spine, femoral neck, or total hip.

3. BMD in the “osteopenia” range (particularly if T is < -2.0) together with factors strongly associated with fracture risk (e.g., hypogonadism or early menopause, treatment with glucocorticoids or antiestrogens).

Some situations require an individualised assessment of the clinical characteristics. In young women with only slightly low BMD and no fractures or other risk factors, delaying treatment can be considered because the absolute risk of fracture is low. By contrast, the coincidence of several important risk factors may lead to earlier treatment consideration. Scales that help estimate fracture risk (e.g., FRAX) may be helpful, although their validity in the Spanish population is limited.

2. Control of the therapeutic response
If necessary, adherence to treatments can be monitored using BTMs, whose changes predict therapeutic response.

The beneficial effect of the treatment is confirmed by the evolution of BMD and the absence of new fractures. A change of treatment may be considered due to a possible inadequate response if two new fractures appear during treatment or two of the following events occur: a new fracture, a significant decrease in BMD (e.g., 4-5%), or a decrease of the BTM less than the minimum significant change (approximately 25%).

<table>
<thead>
<tr>
<th>Table 1. Osteoporosis risk factors</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Factors clearly associated with osteoporosis</td>
</tr>
<tr>
<td>- Advanced age</td>
</tr>
<tr>
<td>- Female sex</td>
</tr>
<tr>
<td>- Personal history of fracture</td>
</tr>
<tr>
<td>- Family history of hip fracture</td>
</tr>
<tr>
<td>- Increased risk of falls</td>
</tr>
<tr>
<td>- Diseases</td>
</tr>
<tr>
<td>- Hypogonadism</td>
</tr>
<tr>
<td>- Early menopause, amenorrhea</td>
</tr>
<tr>
<td>- Anorexia nervosa</td>
</tr>
<tr>
<td>- Malabsorption</td>
</tr>
<tr>
<td>- Rheumatoid arthritis</td>
</tr>
<tr>
<td>- Diabetes (particularly type 1)</td>
</tr>
<tr>
<td>- Immobilisation</td>
</tr>
<tr>
<td>- Cushing’s disease</td>
</tr>
<tr>
<td>- Treatments</td>
</tr>
<tr>
<td>- Glucocorticoids</td>
</tr>
<tr>
<td>- Aromatase inhibitors</td>
</tr>
<tr>
<td>- Gonadotropin-releasing hormone agonists</td>
</tr>
<tr>
<td>(and other androgen deprivation treatments in men)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Table 2. Diagnostic criteria for osteoporosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>- Normal: BMD $T &gt; 1$</td>
</tr>
<tr>
<td>- Osteopenia or low bone mineral density: BMD $T &lt; 1$ and $&gt; -2.49$</td>
</tr>
<tr>
<td>- Osteoporosis: BMD $T &lt; -2.5$</td>
</tr>
<tr>
<td>- Severe osteoporosis: BMD $T &lt; -2.5$ + fracture</td>
</tr>
</tbody>
</table>

BMD: bone mineral density; $T$ (T-score or T index): comparison with the BMD value reached in a young reference population.
3. Duration of treatment
Several aspects must be considered. Although the treat-to-target strategy is theoretically attractive, the aims to be achieved in treating osteoporosis are not well defined, limiting its practical application. For some experts, the absence of new fractures and an increase in BMD would be the most appropriate. Various experts have recommended a T score greater than -2.0 or -2.5 as a target, especially in the hip. Several studies demonstrated the persistence of the effect by maintaining zoledronate for 6 years or alendronate or denosumab for 10 years. However, side effects (particularly ONJ and AFF) may increase with the duration of treatment. Therefore, it is recommended to reassess patients treated with BP at 3 (zoledronate) or 5 years (oral BP) and those treated with denosumab at 5-10 years.

Treatment should be continued (with the same drug or with another) if any of the following circumstances occur:
- BMD at the femoral neck < -2.5 T.
- The appearance of fragility fractures in the 3-5 years before evaluation.
- Some experts also recommend continuing treatment if the patient has a history of hip or vertebral fracture at some point in life.

If none of these circumstances occurs, treatment with BP can be withdrawn, at least temporarily ("therapeutic holidays"): For risendronate, 1 year; for alendronate, 2 years; and for zoledronate, 3 years. In the case of denosumab, temporary interruptions should not be considered.

4. Sequential and combined treatment
4.1. Bisphosphonates after denosumab
After discontinuation of denosumab, bone turnover increases beyond baseline values ("rebound effect"). This is associated with a rapid decrease in bone mass gained and vertebral fractures in some cases. To avoid this occurrence, a powerful BP should be administered. The first dose of zoledronate should be prescribed when denosumab is discontinued (i.e., 6 months after the last dose) and repeated when elevated BTMs are detected, generally at 6 or 12 months.

If the BTMs cannot be measured, the administration of zoledronate should be repeated 6 and 12 months after the previous administration, and the need for new doses should be individually considered. In patients who have received denosumab for fewer than 2.5 years, alendronate can be used instead of zoledronate.
4.2. Antiresorptive agents after anabolics
After finishing treatment with anabolic drugs such as teriparatide or romosozumab, the administration of a BP or denosumab is recommended.

4.3. Anabolic drugs after antiresorptives drugs
The previous use of BP slightly reduces the BMD gain obtained with teriparatide. Therefore, the preferred sequence is first an anabolic drug and then an antiresorptive. However, previous treatment with BP does not contraindicate the administration of anabolics. Of course, teriparatide should not be started as the only treatment in the months after stopping denosumab, given the risk of the accelerated loss of bone mass.

4.4. Combined treatment
There are not enough trials to recommend it routinely. The combination of teriparatide with denosumab or zoledronate may be considered in particularly severe cases with a high risk of hip fracture.

5. Therapeutic decision algorithms

5.1. Initial treatment (choice of drug, figure 1)
The main criterion for the choice of the initial drug is the level of fracture risk:

1) **Moderate risk**: This level corresponds to the risk profile of a woman under 65 years of age, with no history of fracture, moderately low BMD in the spine (T score between -2.5 and -3.0) and preserved in the hip (T score >-2). In this situation, it is advisable to use a SERM and then delay the use of drugs with possible long-term adverse effects. Iblandronate and other antiresorptives are alternative options.

2) **High risk**: This level corresponds to most of the cases. Alendronate, risedronate, zoledronate, and denosumab are indicated. Oral BPs are preferred in patients without inconveniences for oral administration (digestive problems, polypharmacy, adherence) and preferably under 75 years of age.

3) **Very high risk**: This level corresponds to women with a) 2 or more vertebral fractures, or equivalent situation (e.g., vertebral and hip fracture); or b) very low BMD (T score <-3.5; or c) vertebral or hip fracture together with T score <-3.0. There may be other situations (difficult to systematise) in which clinical factors determine very high fracture risk and require individualised consideration. For this level of risk, bone-forming drugs are preferable.

5.2. Long-term treatment (figure 2)
Romosozumab should only be given for 1 year and teriparatide for 2 years. SERMs can be continued for 8 years or until the patient reaches 65-70 years. Then it will be necessary to administer another antiresorptive, BP or denosumab.

---

**Figure 2. Long-term treatment continuation algorithm**

- **Teriparatide**
  - 2 years
  - Continue with BP
    - Every 2-3 y. assess criteria temporary interruption
    - No: Continue BP
  - >10 y. (oral BP or >6 y. [zole])
    - *: Suspend treatment
  - >10 y. (oral BP or >6 y. [zole])
    - *: Continue treatment
    - *: Change to teriparatide

- **Romosozumab**
  - 1 year

- **Long-term treatment**
  - Alendronate - Risedronate
    - 5 years
    - Temporary interruption criteria
  - Zoledronate
    - 3 years
    - Yes: BP reintroduction
    - Cycles temporary interruption-BP
  - Denosumab
    - 10 years
    - Interruption

- **SERM**
  - 8 years (or age 65-70)

- **Dmab <2.5 y.**
  - Bisphosphonates
  - Oral BP 2 years

- **Dmab >2.5 y. or high risk**
  - Zoledronate
    - 1st dose at 6 m. after last denosumab injection
    - BTM control every 3-6 m. and 2nd dose when they increase (usually 12 months)
    - If BTM are not available, 2nd and 3rd dose at 6 and 12 m.

---

*): there are not enough data to establish a recommendation after that treatment time, so the possible options are listed before a decision that must be individualized.

BP: bisphosphonates; SERM: selective estrogen receptor modulators; BTM: bone turnover markers.
The continued use of denosumab is recommended for 5–10 years. There is no information available regarding more prolonged use, so at that time, continuing treatment or discontinuing it should be carefully considered. In any case, a BP should be administered subsequently.

After the initial treatment cycle with BP, an interruption can be considered if the requirements to start a "therapeutic holiday" are met (see the end of section 3). No quality studies are available to guide decision making after 10 years.

**MALE OSTEOPOROSIS**
Most of the drugs have shown gains in BMD like those observed in women, suggesting that their efficacy for fractures is also similar. Alendronate, risendronate, and zoledronate have been shown to reduce vertebral fractures in men. Denosumab has been shown to increase BMD in men and reduce fracture risk in those undergoing androgen deprivation. Teriparatide has also shown beneficial effects in men. For this reason, a strategy for choosing a drug like that for women should be proposed for men: a) risendronate or alendronate (although the latter is not approved in Spain for treating male osteoporosis) as the treatment of choice for most patients; b) zoledronate or denosumab in the elderly or when the oral route is not advisable; and c) teriparatide in very high-risk patients.

**GLUCOCORTICOID-INDUCED OSTEOPOROSIS**
The drugs of choice are BPs. If there are vertebral fractures, preferential treatment with teriparatide is justified due to its greater anti-fracture effect. Calcium and vitamin D should also be given.

Postmenopausal women and men older than 50 years who are to receive doses of ≥5 mg/d of prednisone for >3 months should be treated. In premenopausal women and men <50 years of age, treatment is indicated only if there are previous fractures, BMD is low, or the dose of glucocorticoids is very high (>30 mg/d). Denosumab is an alternative when other antiresorptive agents cannot be used.

The authors’ conflicts of interest are detailed in annex II of the full version of the Guide.

**Additional material**
The full text is available in the Guide.

**Additional material. Annex**
Members of the SEIOMM Expert Group for the revision of the Osteoporosis Guidelines.

**Funding:** This guide has been produced with the administrative support of the SEIOMM, without public or private funding.
Annex

The members of the SEIOMM Expert Group for the revision of the Osteoporosis Guidelines are:

- Cannata Andia, Jorge. Departamento de Medicina. Universidad de Oviedo. Oviedo.
- Casado Burgos, Enrique. Servicio de Reumatología. Hospital Universitari Parc Taulí. Instituto de Investigación e Innovación Parc Taulí. Sabadell (Barcelona).
- del Pino Montes, Javier. Servicio de Reumatología Hospital Universitario Salamanca. Salamanca.
- Del Río Barquero, Luis Miguel. CETIR Centro Médico. Barcelona.
- Díez Pérez, Adolfo. Instituto Hospital del Mar de Investigación Médica. Barcelona.
- Gómez Alonso, Carlos. UGC Metabolismo Óseo. Hospital Universitario Central de Asturias. ISPA. Universidad de Oviedo. Oviedo.
- Gómez de Tejada Romero, María Jesús. Departamento de Medicina. Universidad de Sevilla. Sevilla.
- Naves Díez, Manuel. Unidad de Gestión Clínica de Metabolismo Óseo. Hospital Universitario Central de Asturias. ISPA. RedinREN del ISCIII. Oviedo.
- Nolla, Joan M. Servicio de Reumatología. IDIBELL-Hospital Universitari de Bellvitge. Barcelona.
- Olmos Martínez, José Manuel. Servicio de Medicina Interna. Hospital Universitario Marqués de Valdecilla-IDIVAL. Universidad de Cantabria. Santander.
- Pérez-Castrillón, José Luis. Hospital Universitario Río Hortega. Universidad de Valladolid. Valladolid.
- Riancho, José A. Servicio de Medicina Interna. Hospital Universitario Marqués de Valdecilla-IDIVAL. Universidad de Cantabria. Santander.
- Rodríguez García, Minerva. Servicio de Nefrología. Hospital Universitario Central de Asturias. Oviedo.
Bibliography


